Key facts
- Quadlytics’s last known valuation is $8.3M (May 2025).
- It has raised $2.4M; the latest was Early Stage VC ($2.1M) in May 2025.
- Notable investors include Japan External Trade Organization, XTech Ventures, Kyoto Capital Partners (Japan), Mayo Clinic Platform, CrossTech Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Quadlytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Quadlytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Quadlytics
Developer of epileptic seizure prediction technology designed to detect physiological changes before symptoms appear. The company offers heart rate variability-based sensing and continuous risk evaluation with analytics, enabling patients and healthcare providers to make earlier interventions and improved self management of seizure-related events.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2018
- Employees
- 8
- Website
- quadlytics.com/
- Ownership
- Privately Held (backing)
Quadlytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quadlytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quadlytics in its N-PORT filings yet. We sweep new filings monthly.